<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00655343</url>
  </required_header>
  <id_info>
    <org_study_id>AP-AS-21-DE</org_study_id>
    <nct_id>NCT00655343</nct_id>
  </id_info>
  <brief_title>Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)</brief_title>
  <official_title>GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neovii Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Medical Center Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Neovii Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim is to evaluate the influence of the anti-T-lymphocyte globulin ATG-Fresenius S
      given pre-transplant in addition to standard GvHD prophylaxis with cyclosporine A and a short
      course of methotrexate with respect to efficacy and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the efficacy of ATG-FRESENIUS S in addition to standard therapy (cyclosporine A /
      methotrexate) with respect to early treatment failure defined by the occurrence of severe
      acute GvHD grade III-IV or early mortality within 100 days post transplantation compared to
      standard therapy alone.

      All patients receive myeloablative therapy. Recommended regimens: For patients with ALL:
      fractionated TBI (8-12 Gy) plus cyclophosphamide (1-2 x 60 mg/kg) [etoposide/melfalan are
      also allowed]. For all other indications: either TBI (8-12 Gy) or busulfan (per os 14-16
      mg/kg b.w. or equivalent for IV administration) plus cyclophosphamide (1-2 x 60 mg/kg) or
      thiotepa ≥ 15 mg/kg or BCNU ≥ 300 mg/m2.

      Conditioning regimens may differ from centre to centre; each centre decides for constant
      (disease specific) regimen(s) throughout the whole study period.

      Standard GvHD prophylaxis consists of cyclosporine A (target trough level ≥ 200 ng/ml
      starting from day -1 until day +100) and short course methotrexate (15 mg/m2 at day +1, 10
      mg/m2 at days +3, +6 and +11).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: Early treatment failure defined by the occurrence of severe acute GvHD (°III-°IV) or early mortality within 100 days post transplantation.</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to onset of acute GvHD, incidence and severity of infections until day +100, time to engraftment, incidence of cGvHD, disease free survival, relapse, death without relapse, overall survival, safety, tolerability.</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>ATG-F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG-Fresenius S (20 mg/kg body weight at days -3 to -1 (total dose: 60 mg/kg)
cyclosporine A (target trough level &gt; 200ng/ml (day -1 until day +100)
methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-ATG-F</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>cyclosporine A (target trough level &gt; 200ng/ml (day -1 until day +100)
methotrexate: 15mg/m2 at day +1, 10mg/m2 at days +3, +6, and +11</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG-Fresenius S</intervention_name>
    <description>20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution
20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation</description>
    <arm_group_label>ATG-F</arm_group_label>
    <other_name>ATG-Fresenius</other_name>
    <other_name>Anti-T-Lymphocyte globulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participation of patients in simultaneous diagnostic and comprehensive therapeutical trials
        for certain entities is allowed.

          -  Patients 18-60 years of age;

          -  Patients suffering from one of the following diseases:

               -  AML: 1st complete remission (CR1) or beyond 1st remission (CR2, CR3), in relapse,
                  not in remission (primary refractory, induction failure);

               -  ALL: 1st complete remission (CR1) or beyond 1st remission (CR2, CR3), in relapse,
                  not in remission (primary refractory, induction failure);

               -  MDS, if transplantation is medically indicated: RA (with poor risk factors as
                  classified by the International Prognostic Scoring System of MDS), RARS, RAEB,
                  RAEB-t, CMML;

               -  CML: beyond 1st chronic phase (CP1): accelerated phase, blast crisis, chronic
                  phase (CP2, CP3);

               -  OMF, if transplantation is medically indicated: Osteomyelofibrosis;

          -  Patients designated to undergo allogeneic bone marrow transplantation or allogeneic
             peripheral blood stem cell transplantation;

          -  Patients with a HLA-A, -B (DNA-based, 2 digits), HLA-DRB1, -DQB1 (DNA-based 4 digits)
             matched (8 out of 8 alleles) unrelated donor; serological typing is not required

          -  Patients with a Karnofsky Performance Score (KPS): &gt; 60%;

          -  Patients who underwent all obligatory screening examinations (special examinations
             within the last 4 weeks);

          -  Patients who have given their written informed consent to participate in the study.

        Exclusion Criteria:

          -  Patients with significant cardiac (e.g. ejection fraction &lt;50%), pulmonary (e.g. FEV1
             &lt;50%), renal (e.g. creatinine &gt; 1.5 mg/dl), metabolic (e.g. bilirubin &gt; 2.0 mg/dl)
             and/or CNS disease, currently uncontrolled by treatment, which may interfere with the
             completion of the study;

          -  Patients with any bacterial, viral, or fungal infections not under adequate
             antimicrobial control;

          -  Patients who are known to have serum hepatitis or who are carriers of the Hepatitis B
             surface antigen (HBs-Ag), or Hepatitis C antibody, or who are known to have a positive
             result to the test of HIV antibodies;

          -  Patients with any additional concurrent or previous malignant disease;

          -  Patients with known hypersensitivity to rabbit immunoglobulin antibodies in past
             patient history or with known allergy to any substance chemically related to the study
             medication;

          -  Pregnant (β-HCG test) or lactating women;

          -  Patients who formerly underwent transplantation including previous autologous
             transplants;

          -  Patients who cannot communicate reliably with the investigator or who are not likely
             to cope with the requirements of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Finke, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert-Ludwigs-University Freiburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universität Freiburg, Medizinische Klinik, Abteilung Innere Medizin I, Hämatologie/Onkologie</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J; ATG-Fresenius Trial Group. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011 Jun 9;117(23):6375-82. doi: 10.1182/blood-2011-01-329821. Epub 2011 Apr 5.</citation>
    <PMID>21467544</PMID>
  </results_reference>
  <results_reference>
    <citation>Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009 Sep;10(9):855-64. doi: 10.1016/S1470-2045(09)70225-6. Epub 2009 Aug 18.</citation>
    <PMID>19695955</PMID>
  </results_reference>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2008</study_first_posted>
  <last_update_submitted>December 9, 2011</last_update_submitted>
  <last_update_submitted_qc>December 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GvHD</keyword>
  <keyword>aGvHD prophylaxis</keyword>
  <keyword>Matched unrelated donor</keyword>
  <keyword>ATG</keyword>
  <keyword>SCT</keyword>
  <keyword>BMT</keyword>
  <keyword>polyclonal antibody</keyword>
  <keyword>GvHD prophylaxis for patients with ALL, AML, CML, MDS, OMF</keyword>
  <keyword>Patients with allogeneic BM or PBSC transplantation</keyword>
  <keyword>Patients with a matched unrelated donor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

